Previous studies have reported that PAX1 methylation testing is a potential biomarker for the screening of cervical cancer with a sensitivity and specificity greater than 80% in the detection of grade III or higher cervical intraepithelial neoplasia (CIN3+) lesions [32,33]. This evidence concerns the gene PAX1 and cervical cancer.